Literature DB >> 22893577

Free light chains and the risk of AIDS-defining opportunistic infections in HIV-infected individuals.

Meredith S Shiels1, Ola Landgren, Rene Costello, Adriana Zingone, James J Goedert, Eric A Engels.   

Abstract

BACKGROUND: The relevance of B-cell dysfunction for progression to AIDS among human immunodeficiency virus (HIV)-infected individuals has not been clearly defined. We evaluated the association between circulating κ and λ free light chains (FLCs), which are markers of B-cell dysfunction, and risk of developing an AIDS-defining opportunistic infection in HIV-infected men.
METHODS: The study included 252 case patients with clinical AIDS and 252 HIV-infected controls from the Multicenter Hemophilia Cohort Study I. Case patients were matched to controls on birth date, specimen type, blood sample collection date, and CD4 cell count. Levels of κ and λ FLCs were measured in serum or plasma collected 0-2.5 years before selection. Elevated FLC levels (κ or λ, above the upper limit of normal) were classified as polyclonal (normal κ-λ ratio) or monoclonal (abnormally skewed κ-λ ratio). We used conditional logistic regression to estimate odds ratios (ORs) for AIDS.
RESULTS: FLC levels were higher in case patients than in controls, for κ (median, 4.03 vs 2.98 mg/dL) and λ (3.77 vs 2.42 mg/dL) FLCs. Compared with normal levels, above-normal FLC levels were associated with AIDS (OR, 3.13 [95% confidence interval (CI), 1.78-5.49] for κ and 3.47 [2.31-5.20] for λ FLCs), and the association with AIDS was strengthened with increasing κ and λ FLC levels (P trends < .0001). Polyclonal FLC elevation was associated with a 4-fold increase in the risk of AIDS (OR, 3.85; 95% CI, 1.97-7.54), but monoclonal FLC elevation was not associated with AIDS.
CONCLUSIONS: Circulating FLCs are associated with elevated risk of AIDS in HIV-infected individuals. Polyclonal B-cell dysfunction may contribute to HIV-related immune suppression and predispose to clinical AIDS events.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22893577      PMCID: PMC3478141          DOI: 10.1093/cid/cis692

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  20 in total

1.  Polyclonal immunoglobulin free light chains as a potential biomarker of immune stimulation and inflammation.

Authors:  Colin A Hutchison; Ola Landgren
Journal:  Clin Chem       Date:  2011-10       Impact factor: 8.327

2.  Relation between soluble CD30 levels measured soon after HIV seroconversion and disease progression in men with hemophilia.

Authors:  C A Sabin; M Bofill; A N Phillips; J Elford; G Janossy; C A Lee
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-12-01

3.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

Authors:  S M Hammer; K E Squires; M D Hughes; J M Grimes; L M Demeter; J S Currier; J J Eron; J E Feinberg; H H Balfour; L R Deyton; J A Chodakewitz; M A Fischl
Journal:  N Engl J Med       Date:  1997-09-11       Impact factor: 91.245

4.  HIV-1 infection incidence among persons with hemophilia in the United States and western Europe, 1978-1990. Multicenter Hemophilia Cohort Study.

Authors:  B L Kroner; P S Rosenberg; L M Aledort; W G Alvord; J J Goedert
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1994-03

5.  Infections in chronic lymphocytic leukemia. Analysis of incidence as a function of length of follow-up.

Authors:  S Molica; D Levato; L Levato
Journal:  Haematologica       Date:  1993 Nov-Dec       Impact factor: 9.941

6.  High serum level of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of progression to AIDS.

Authors:  G Pizzolo; F Vinante; L Morosato; G Nadali; M Chilosi; G Gandini; A Sinicco; R Raiteri; G Semenzato; H Stein
Journal:  AIDS       Date:  1994-06       Impact factor: 4.177

Review 7.  B lymphocyte dysfunctions in HIV infection.

Authors:  Angelo De Milito
Journal:  Curr HIV Res       Date:  2004-01       Impact factor: 1.581

8.  Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome.

Authors:  H C Lane; H Masur; L C Edgar; G Whalen; A H Rook; A S Fauci
Journal:  N Engl J Med       Date:  1983-08-25       Impact factor: 91.245

9.  1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1992-12-18

10.  Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.

Authors:  Jerry A Katzmann; Raynell J Clark; Roshini S Abraham; Sandra Bryant; James F Lymp; Arthur R Bradwell; Robert A Kyle
Journal:  Clin Chem       Date:  2002-09       Impact factor: 8.327

View more
  2 in total

1.  Serum free light-chain assay for the detection and monitoring of multiple myeloma and related conditions.

Authors:  Patrizia Tosi; Simona Tomassetti; Anna Merli; Valentina Polli
Journal:  Ther Adv Hematol       Date:  2013-02

2.  Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease.

Authors:  Thomas S Uldrick; Mark N Polizzotto; Karen Aleman; Kathleen M Wyvill; Vickie Marshall; Denise Whitby; Victoria Wang; Stefania Pittaluga; Deirdre O'Mahony; Seth M Steinberg; Richard F Little; Robert Yarchoan
Journal:  Blood       Date:  2014-10-20       Impact factor: 22.113

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.